Literature DB >> 18078690

The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function.

Yosuke Iizumi1, Hiroshi Sagara, Yasuaki Kabe, Motoki Azuma, Kanako Kume, Michinaga Ogawa, Takeshi Nagai, Peter G Gillespie, Chihiro Sasakawa, Hiroshi Handa.   

Abstract

Enteropathogenic Escherichia coli (EPEC) destroys intestinal microvilli and suppresses phagocytosis by injecting effectors into infected cells through a type III secretion system (TTSS). EspB, a component of the TTSS, is also injected into the cytoplasm of host cells. However, the physiological functions of EspB within the host cell cytoplasm remain unclear. We show that EspB binds to myosins, which are a superfamily of proteins that interact with actin filaments and mediate essential cellular processes, including microvillus formation and phagocytosis. EspB inhibits the interaction of myosins with actin, and an EspB mutant that lacks the myosin-binding region maintained its TTSS function but could not induce microvillus effacing or suppress phagocytosis. Moreover, the myosin-binding region of EspB is essential for Citrobacter rodentium, an EPEC-related murine pathogen, to efficiently infect mice. These results suggest that EspB inhibits myosin functions and thereby facilitates efficient infection by EPEC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078690     DOI: 10.1016/j.chom.2007.09.012

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  39 in total

Review 1.  Plasticity of the brush border - the yin and yang of intestinal homeostasis.

Authors:  Delphine Delacour; Julie Salomon; Sylvie Robine; Daniel Louvard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-03       Impact factor: 46.802

Review 2.  Bacteria in the intestine, helpful residents or enemies from within?

Authors:  Geraldine O Canny; Beth A McCormick
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

3.  Interactions and predicted host membrane topology of the enteropathogenic Escherichia coli translocator protein EspB.

Authors:  Wensheng Luo; Michael S Donnenberg
Journal:  J Bacteriol       Date:  2011-04-15       Impact factor: 3.490

4.  Fascin, may the Forked be with you.

Authors:  Pilar Okenve-Ramos; Marta Llimargas
Journal:  Fly (Austin)       Date:  2014-10-31       Impact factor: 2.160

Review 5.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  Molecular mechanisms of Escherichia coli pathogenicity.

Authors:  Matthew A Croxen; B Brett Finlay
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

7.  Detection of secretory immunoglobulin A in human colostrum as mucosal immune response against proteins of the type III secretion system of Salmonella, Shigella and enteropathogenic Escherichia coli.

Authors:  David Durand; Theresa J Ochoa; Sicilia M E Bellomo; Carmen A Contreras; Víctor H Bustamante; Joaquim Ruiz; Thomas G Cleary
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

8.  Molecular model of the microvillar cytoskeleton and organization of the brush border.

Authors:  Jeffrey W Brown; C James McKnight
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.

Authors:  Sylvia Kleta; Marcel Nordhoff; Karsten Tedin; Lothar H Wieler; Rafal Kolenda; Sibylle Oswald; Tobias A Oelschlaeger; Wilfried Bleiss; Peter Schierack
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

Review 10.  All blood, no stool: enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Jang W Yoon; Carolyn J Hovde
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.